Real-world utilization of lenvatinib and pembrolizumab combination therapy for the treatment of endometrial cancer in the USA.
Future Oncol
; 20(5): 257-267, 2024 Feb.
Article
en En
| MEDLINE
| ID: mdl-37828843
This study looked at details of lenvatinib and pembrolizumab combination treatment among patients with endometrial cancer (EC) in the USA. Specifically, these patients had received prior chemotherapy or hormone therapy before starting lenvatinib and pembrolizumab. Most patients started lenvatinib and pembrolizumab at the dose recommended by the product label and received the next pembrolizumab injection within the recommended timeframe. Over time, more than half of the patients did not change the dose of lenvatinib, and most patients had the same dose of pembrolizumab. On average, patients were treated with lenvatinib and pembrolizumab for 56 months. This study showed that in general, patients were taking lenvatinib and pembrolizumab for treatment of EC as recommended by product labels.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Quinolinas
/
Neoplasias Endometriales
/
Anticuerpos Monoclonales Humanizados
Límite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Future Oncol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos